Amphastar Pharmaceuticals (AMPH) Q4 2024 Annual Earnings
AMPH·Reported February 27, 2025·After market close
Amphastar Pharmaceuticals reported Q4 2024 revenue of $186.5M, missed analyst consensus of $188.8M by $2.3M. Diluted EPS came in at $0.92, missed the $1.01 consensus by $0.09.
Revenue
$186.5Mmissed by $2.3M
Consensus: $188.8MDiluted EPS
$0.92missed by $0.09
Consensus: $1.01
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Amphastar Pharmaceuticals's Q4 2024 earnings report.
Amphastar Pharmaceuticals (AMPH) reported Q4 2024 earnings on February 27, 2025 after market close.
Amphastar Pharmaceuticals reported revenue of $186.5M and diluted EPS of $0.92 for Q4 2024.
Revenue missed the consensus estimate of $188.8M by $2.3M. EPS missed the consensus estimate of $1.01 by $0.09.
You can read the 10-K periodic report (0001297184-25-000008) directly on SEC EDGAR. The filing index links above go to sec.gov.